Volume : 09, Issue : 01, January – 2022
Title:
27.PREVALENCE AND CLINICAL FEATURES OF COVID19 AMONG HOSPITALIZED PATIENTS WITH HEMOGLOBINOPATHY IN EASTERN PROVINCE OF SAUDI ARABIA, CROSS SECTIONAL STUDY, 2020
Authors :
Nariman Al-shakhis, Esra Al-zaid, Rahma Al-Gadeeb, Kefah Al-Gadeeb,Mustafa Al-Ajwad, Manahil Nouri, Hawra Al-Sheef, Albatool Al-Wesaibi, Mohammed Al-Matar, Ali Al-Muraikhi, Abdullah Al-Kalaf, Haidar Al-Alaqaili, Hashem Al-kalifah
Abstract :
Background: Patients with Hemoglobin disorders have weak immune system. Patients with sickle cell have auto-splenectomy and use hydroxyurea treatment which could cause further immunosuppression. This fact is thought to increases the risk of acquiring COVID 19 infection specially if they were older and have other co-morbid illnesses as diabetes or cancer. At April 12, 2020 Ministry of health shared the first version of Rapid Response Guidelines on COVID19 in Sickle Cell Disease. The guideline was based on expert opinion since no studies have been published to study this special population.
Aim: To study prevalence and clinical features of hospitalized patients with hemoglobinopathies and confirmed COVID-19 in the eastern province of Saudi Arabia.
Methods: A descriptive cross-sectional study was conducted in two major hospitals in the eastern province of Saudi Arabia from March 2020 to September 2020. Data for patients with confirmed COVID19 and hemoglobinopathy were collected from electronic medical files. descriptive and analytic inferential statistics was conducted.
Results: There were 1122 patients (700 from King Fahad Hospital in Al-Hassa and 422 from Dammam Hospital) admitted due COVID-19 from March 2020 to September 2020. Among them, 43 patients had been diagnosed with hemoglobinopathy, giving an overall prevalence rate of 3.83%. The most common type of hemoglobin disorder was sickle cell disease (53.5%) followed by sickle cell trait (27.9%). mean duration of hospital stay was 18.7 (SD 43.5) days. it was observed that the duration of hospital stay of patients who were taking antiviral medication (p=0.009) and hydroxychloroquine (p=0.019) were significantly longer.
Conclusion: Saudi Arabia showed higher prevalence of COVID-19 infection in patients with hemoglobinopathies in comparison to other countries worldwide. This is ought to the fact that Eastern province is one of the most prevalent areas for patients hemoglobinopathies. researchers found that despite a large population of patients with hemoglobinopathies in our area, COVID 19 patients with SCD or thalassemia who required hospital care, oxygenation or ICU admission were less than the non-hemoglobinopathies patients.
Key Words: Hemoglobinopathy, Covid-19 , Sickle cell ,Thalassemia , Saudi Arabia .
Cite This Article:
Please cite this article in press Nariman Adeeb Al-shakhis et al, Prevalence And Clinical Features Of Covid19 Among Hospitalized Patients With Hemoglobinopathy In Eastern Province Of Saudi Arabia, Cross Sectional Study, 2020., Indo Am. J. P. Sci, 2022; 09(01).
Number of Downloads : 10
References:
1. Novel coronavirus 2019 (COVID‐19): Emergence and implications for emergency care. Available from: https://www.researchgate.net/publication/339436556_Novel_coronavirus_2019_COVID-19_Emergence_and_implications_for_emergency_care [accessed Apr 16 2020].
2. Coronavirus [Internet]. Who.int. 2020 [cited 16 April 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
3. Coronaviruses | NIH: National Institute of Allergy and Infectious Diseases [Internet].Niaid.nih.gov. 2020 [cited 16 April 2020]. Available from: https://www.niaid.nih.gov/diseases-conditions/coronaviruses
4. Coronavirus [Internet]. Who.int. 2020 [cited 16 April 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
5. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Jul;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006. Epub 2020 Apr 12.
6. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Accessed April 18, 2020.
7. Amir Emami, Fatemeh Javanmardi, Ali Akbari,Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis , Arch Acad Emerg Med. 2020; 8(1): e35.
8. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. Available from: https://www.gov.uk/government/publications/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19. Accessed April 18, 2020.
9. COVID -19 in sickle cell, Rapid Response Guidelines Version 1.1 . Available from: https://www.moh.gov.sa/Ministry/MediaCenter/Publications/Documents/COVID19-in-Sickle-Cell-Disease.pdf
10. CDC (2019-02-08). “Hemoglobinopathies Research”. Centers for Disease Control and Prevention. Retrieved 2019-05-05
11. Weatherall DJ, Clegg JB: The thalassaemia syndromes. 4th Edition. Oxford: Blackwell Science Ltd 2001.
12. Kohne E, Kleihauer E: Hemoglobinopathies in Germany—a longitudinal study over four decades. Dtsch Arztebl Int 2010; 107: 65–72.
13. Alsaeed ES, Farhat GN, Assiri AM, Memish Z, Ahmed EM, Saeedi MY, Al-Dossary MF, Bashawri H. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. Journal of epidemiology and global health. 2018 Mar;7 Suppl 1:S41-S47. doi: 10.1016/j.jegh.2017.12.001
14. Memish ZA, Saeedi M. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and [beta]-thalassemia in Saudi Arabia. Annals of Saudi Medicine. 2011 May 1;31(3):229. doi: 10.4103/0256-4947.81527
15. AlHamdan NA, AlMazrou YY, AlSwaidi FM, Choudhry A. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genetics in Medicine. 2007 Jun;9(6):372. DOI: 10.1097GIM.0b013e318065a9e8.
16. [ONLINE] Available at https://en.wikipedia.org/wiki/2020_coronavirus_pandemic_in_Saudi_Arabia#cite_note-2
17. [ONLINE] Available at https://en.wikipedia.org/wiki/Eastern_Province,_Saudi_Arabia
18. [ONLINE] Available at https://covid19.moh.gov.sa/
19. Hypertension Canada. Hypertension Canada’s statement on: hypertension, ACEI inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-HypertensionCanada-Statement-on-COVID-19-ACEi-ARB.pdf. Published March 13, 2020. Accessed March 23, 2020.
20. American Heart Association. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment. March 2020. Available at : https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contractcovid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician.
21. [ONLINE] Available at www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-nonsteroidal-anti-inflammatory-drugs-nsaids-covid-19.
22. Kashari O, Alghamdi B, Al-Hebshi A, Asiri A, Fallatah E, Alshehri F, Alsamiri S, Masmali H, Nabulsi M, Assiri M, Alwasaidi TA. COVID-19 in Saudi Patients With Sickle Cell Disease: A Retrospective Multi-Center Study. Cureus. 2021 Aug 16;13(8):e17238. doi: 10.7759/cureus.17238. PMID: 34422504; PMCID: PMC8369254.
23. Abdulqader Al‐Hebshi, Mohammed Zolaly, Amer Alshengeti, Ghaya Al Qurainees, Sofyan Yamani, Naif Hamdan and Turki Alwasaidi .A Saudi family with sickle cell disease presented with acute crises and COVID‐19 infection
24. Vincenzo de Sanctis, Duran Canatan, Joan Lluis Vives Corrons, Mehran Karimi,Shahina Daar, Christos Kattamis,Ashraf T. Soliman, Yasser Wali,Salam Alkindi, Valeh Huseynov,Afag Nasibova, Tarık Onur Tiryaki,Melike Sezgin Evim, Adalet Meral Gunes, Zeynep Karakas,Soteroula Christou, Saveria Campisi, Tahereh Zarei,Doaa Khater,Yesim Oymak, Valeriya Kaleva,Denka Stoyanova,Atanas Banchev, Maria Concetta Galati, Mohamed A Yassin,Shruti Kakar,Myrto Skafida,Yurdanur Kilinc, (Participants), Saif Alyaarubi, Narmin Verdiyevas, Iva Stoeva,Giuseppe Raiola, Demetris Mariannis, Leopoldo Ruggiero, and Salvatore Di Maio, (Collaborators). Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study. Mediterr J Hematol Infect Dis. 2020; 12(1): e2020046.
25. Telfer P, De la Fuente J, Sohal M, Brown R, Eleftheriou P, Roy N, Piel FB, Chakravorty S, Gardner K, Velangi M, Drasar E. Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. haematologica. 2020 Nov 1;105(11):2651
26. Nino Balanchivadze , Adam A Kudirka , Sally Askar , Khaled Almadhoun , Philip Kuriakose , Raef Fadel , Vrushali Dabak Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA. Hemoglobin. 2020 Jul;44(4):284-289. doi: 10.1080/03630269.2020.1797775. Epub 2020 Jul 28.
27. Jean-Benoît Arlet,a Gonzalo de Luna,b Djamal Khimoud,a Marie-Hélène Odièvre,c Mariane de Montalembert,d Laure Joseph,d Christelle Chantalat-Auger,e Edouard Flamarion,a Pablo Bartolucci,b François Lionnet,f Sebastien Monnier,g Cécile Guillaumat,h and Aline Santinf. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. 2020 Sep; 7(9): e632–e634.
28. Alsaeed ES, Farhat GN, Assiri AM, Memish Z, Ahmed EM, Saeedi MY, Al-Dossary MF, Bashawri H. Distribution of hemoglobinopathy disorders in Saudi Arabia based on data from the premarital screening and genetic counseling program, 2011–2015. Journal of epidemiology and global health. 2018 Mar;7 Suppl 1:S41-S47. doi: 10.1016/j.jegh.2017.12.001
29. Marco Cascella, Michael Rajnik, Arturo Cuomo, Scott C Dulebohn, Raffaela Di Napoli. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Features, Evaluation and Treatment Coronavirus (COVID-19) Jan. 2020 May 18.